Wednesday, June 29, 2011
Wednesday, June 22, 2011
Tuesday, June 21, 2011
Sunday, June 19, 2011
Thursday, June 16, 2011
Liraglutide as Additional Treatment in Type 1 Diabetes
In continuation of my update on Liraglutide...
Results of a small, observational study conducted at the University at Buffalo suggest that liraglutide (below structure) , an injectable medication used to treat type 2 diabetes, also helps type 1 diabetics on insulin achieve optimal control of their blood glucose levels.
More....
Tuesday, June 14, 2011
New drug more effective than standard treatment to prevent heart-attack deaths
In continuation of my update on ticagrelor .....
Robert Storey, Professor of Cardiology at the University of Sheffield's Department of Cardiovascular Science, presented findings today that confirm one in five deaths in the year following a heart attack could be prevented if a new drug, ticagrelor (see structure), was used instead of the standard treatment, clopidogrel...
More...
Labels:
Heart attack,
Ticagrelor (Brilinta)
Wednesday, June 8, 2011
Positive results from Plexxikon's vemurafenib Phase 2 and 3 trial against metastatic melanoma
We know that, PLX-4032(RG7204, Vemurafenib) is a highly selective inhibitor of BRAF kinase activity, with an IC50 of 44 nmol/L against V600E-mutant BRAF. BRAFV600E cancer-causing mutation occurs in most melanomas and about eight percent of all solid tumors....
More....
Labels:
Anticancer,
BRAF kinase activity,
RG7204,
vemurafenib
Tuesday, June 7, 2011
Formoterol drug improves fat burning and protein metabolism in men
We know that, Formoterol or eformoterol is a long-acting β2-agonist used in the management of asthma and/or chronic obstructive pulmonary disease (COPD). It is marketed in four forms: a dry-powder inhaler (DPI), a metered-dose inhaler (MDI), an oral tablet, and an inhalation solution, under various trade names including Foradil/Foradile (Schering-Plough in the U.S., Novartis rest of world), Oxeze (AstraZeneca), Atock (Astellas), Atimos Modulite (Trinity-Chiesi), and Perforomist (Dey).
Now researchers lead by Dr. Paul Lee of Garvan Institute of Medical Research in Sydney, have for the first time reports that research in animals has shown that formoterol can stimulate the growth of muscle and the burning of fat...
Formoterol drug improves fat burning and protein metabolism in men
Labels:
anti-obesity,
Asthma,
formoterol
Friday, June 3, 2011
Lyxumia®, as an add-on to basal Insulin, shows significant positive phase III results
Sanofi announced today that new results from a Phase III study showed that the investigational product Lyxumia® (lixisenatide see structure above), when used as an add-on therapy to basal insulin (in association with or without metformin), achieved its primary efficacy endpoint of significantly reducing HbA1c versus placebo for patientswith type 2 diabetes without significantly increasing their risk of hypoglycemia...
More...
Labels:
Diabetes,
Insulin,
Lyxumia® (lixisenatide)
Subscribe to:
Posts (Atom)